Literature DB >> 18519743

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.

Teresa R Johnson1, Marc E Rothenberg, Barney S Graham.   

Abstract

Severe illness, type 2 cytokine production, and pulmonary eosinophilia are adverse immune responses resulting from respiratory syncytial virus (RSV) challenge of vvGs-immunized mice. We have shown IL-4 and IL-13 activity must be simultaneously inhibited to reduce disease severity. We now address the contributions of IL-5, eotaxin-1, and CD4+ and CD8+ T cells to the induction of disease-enhancing immune responses. Depletion of CD4+ T cells during immunization prevented IL-4, IL-13, and eotaxin-1 production, diminished eosinophilia, and reduced weight loss. Conversely, CD8+ T cell depletion did not decrease eosinophilia, weight loss, or type 2 cytokines but did dramatically reduce mucus production and increase eotaxin production. Anti-IL-5 administration at immunization or challenge significantly decreased pulmonary eosinophilia. Strikingly, there were not concomitant decreases in weight loss. Following RSV challenge eotaxin-1-deficient mice immunized with vvGs exhibited significantly less eosinophilia without decreased weight loss or type 2 cytokine production. We conclude CD4+ T cell production of IL-5 and induction of eotaxin-1 are required for vvGs-induced eosinophilia following RSV challenge, while CD8+ T cells appear to down-regulate eotaxin-1 and mucus production. In summary, we demonstrate that pulmonary eosinophilia 1) is a by-product of memory CD4+ T cell activation, 2) does not necessarily correlate with mucus production, and, most importantly, 3) is not required for the RSV G-induced illness in mice. These findings have important implications for the evaluation of candidate RSV vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519743      PMCID: PMC2516895          DOI: 10.1189/jlb.0907621

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  65 in total

1.  Eotaxins. Contributing to the diversity of eosinophil recruitment and activation.

Authors:  C Bandeira-Melo; A Herbst; P F Weller
Journal:  Am J Respir Cell Mol Biol       Date:  2001-06       Impact factor: 6.914

2.  Effect of vaccination on cell populations in lung washes from calves after infection with respiratory syncytial virus.

Authors:  G Taylor; L H Thomas; E J Stott
Journal:  Res Vet Sci       Date:  1989-09       Impact factor: 2.534

3.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

4.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice.

Authors:  M E Rothenberg; R Ownbey; P D Mehlhop; P M Loiselle; M van de Rijn; J V Bonventre; H C Oettgen; P Leder; A D Luster
Journal:  Mol Med       Date:  1996-05       Impact factor: 6.354

Review 6.  Mechanisms of eosinophil recruitment.

Authors:  M B Resnick; P F Weller
Journal:  Am J Respir Cell Mol Biol       Date:  1993-04       Impact factor: 6.914

7.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response.

Authors:  J A Ganzalo; G Q Jia; V Aguirre; D Friend; A J Coyle; N A Jenkins; G S Lin; H Katz; A Lichtman; N Copeland; M Kopf; J C Gutierrez-Ramos
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

9.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.

Authors:  M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

10.  Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection.

Authors:  R Garofalo; J L Kimpen; R C Welliver; P L Ogra
Journal:  J Pediatr       Date:  1992-01       Impact factor: 4.406

View more
  17 in total

1.  Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.

Authors:  Yung-Chang Su; Dijana Townsend; Lara J Herrero; Ali Zaid; Michael S Rolph; Michelle E Gahan; Michelle A Nelson; Penny A Rudd; Klaus I Matthaei; Paul S Foster; Lindsay Dent; Ralph A Tripp; James Lee; Ljubov Simson; Suresh Mahalingam
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

2.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

3.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Authors:  Teresa R Johnson; Srinivas Rao; Robert A Seder; Man Chen; Barney S Graham
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

Review 4.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

5.  Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; F Eun-Hyung Lee; Sang-Moo Kang
Journal:  Nanomedicine       Date:  2015-12-02       Impact factor: 5.307

6.  Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine.

Authors:  Anja Krause; Yaqin Xu; Sara Ross; Wendy Wu; Ju Joh; Stefan Worgall
Journal:  Virol J       Date:  2011-07-29       Impact factor: 4.099

7.  A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.

Authors:  Stacie L Lambert; Shahin Aslam; Elizabeth Stillman; Mia MacPhail; Christine Nelson; Bodrey Ro; Rosemary Sweetwood; Yuk Man Lei; Jennifer C Woo; Roderick S Tang
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

8.  Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Yu-Jin Jung; Youri Lee; Jong Seok Lee; Yu-Na Lee; Soojin Park; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 9.  Respiratory viruses and eosinophils: exploring the connections.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

10.  Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Authors:  Patricia A Jorquera; Youngjoo Choi; Katie E Oakley; Thomas J Powell; James G Boyd; Naveen Palath; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.